Latest Breaking News On - Upcoming milestones - Page 6 : comparemela.com

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRisvodetinib risvoMiltonh wernerRisvodetinib ikCompany contactExchange commissionInhibikase therapeutics incDivision of hematologic malignanciesSteam reviewInhibikase or companyAlex lobostern investor relations incAbelson tyrosine kinasesChief executive officerUpcoming milestonesHematologic malignanciesMeeting minutes

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Pharmaceuticals, Inc. today announced its 2023 financial results and provided an update on its retinal disease development pipeline. The Company s major initiatives planned for 2024 are to.

Brianm stremCalifornia newsfile corpKiora pharmaceuticals incKiora pharmaceuticalsOpen innovationMelissa toscaUpcoming milestonesOrphan drug designationsPrivate securities litigation reform actAnnual report

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Brianm stremDennis riedlKiora pharmaceuticals incCalifornia newsfile corpKiora pharmaceuticalsOpen innovationMelissa toscaUpcoming milestonesOrphan drug designationsPrivate securities litigation reform actAnnual report

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2.

New zealandSteve connellyArash mostaghimiHarvard medical schoolEquillium incExchange commissionOno pharmaceutical co ltdBioniz therapeutics incBruce steelInvestor dayAnnual peptide therapeutics symposiumUpcoming milestonesFull yearAsset purchase agreementBioniz therapeuticsMulti cytokine platform

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial.

United kingdomUnited statesBlack diamondMark vellecaMario corsoDiamond therapeutics incDrug administrationCompany masterkeyEuropean organization for researchAmerican association for cancer researchIvy brain tumor centerDevelopment expensesExchange commissionNational cancer instituteDiamond therapeuticsChief executive officer